Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript March 20, 2025 Monte Rosa Therapeutics, Inc. beats earnings expectations. Reported EPS is $0 ...
Mixed data results for two Monte Rosa molecular glue degraders
Monte Rosa reported that one of its molecular glue degraders had seen a strong response in immune disorders, but another fell ...
Monte Rosa Therapeutics price target raised to $17 from $15 at Wedbush
Wedbush raised the firm’s price target on Monte Rosa Therapeutics (GLUE) to $17 from $15 and keeps an Outperform rating on the shares after the ...
Monte Rosa Therapeutics shares surge on strong Q4 revenue beat
BOSTON - Monte Rosa Therapeutics , Inc. (NASDAQ: GLUE) reported fourth quarter revenue that significantly exceeded analyst expectations, sending shares up 6.9% in early trading.
Monte Rosa Therapeutics announces results from MRT-6160, MRT-2359 programs
Monte Rosa announced clinical results from its MRT-6160 Phase 1, single ascending dose / multiple ascending dose study. Details about the ...
Nasdaq26d
Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
Monte Rosa has a global license agreement with Novartis to advance VAV1-directed molecular glue degraders and a strategic collaboration with Roche to discover and develop MGDs against targets in ...
eLife9y
Glutaminase 2 is a novel negative regulator of small GTPase Rac1 and mediates p53 function in suppressing metastasis
Glutaminase (GLS) isoenzymes GLS1 and GLS2 are key enzymes for glutamine metabolism. Interestingly, GLS1 and GLS2 display contrasting functions in tumorigenesis with elusive mechanism; GLS1 promotes ...